A Study of Sunvozertinib Combined With Anlotinib in Local Advanced or Metastatic Non-small Cell Lung Cancer

NCT06182761 | Not Yet Recruiting Phase 2

• 1 other identifier: WUKONG9
• Study Type: interventional
• Target: 45
• Locations: 0 countries
• Sites: N/A

Brief Summary

The study will evaluate the efficacy and safety of treatment with sunvozertinib in combination with Anlotinib in patients whose disease has progressed following first-line EGFR-TKIs treatment.

Conditions

NSCLC

Outcome Measures

Primary Outcomes (1)

• ORR

  Objective response rate (ORR) as assessed by the investigator according to RECIST 1.1 criteria.

  initiate from first dose until the date of confirmed response, assessed up to 24 weeks

Secondary Outcomes (4)

• PFS

  initiate from first dose, every 6 weeks until PD or study close, an average of 1 year

• OS

  through study completion, an average of 1.5 years

• DoR

  an average of 1 year

• AE

  through study completion, an average of 1 year

Study Arms (1)

sunvozertinib in combination with Anlotinib

EXPERIMENTAL

Drug: Sunvozertinib combination with Anlotinib

Interventions

Sunvozertinib combination with Anlotinib DRUG

Sunvozertinib 300 mg once daily (QD) with Anlotinib 12mg once daily （QD in Day 1-14） ，21 days in one cycle.

sunvozertinib in combination with Anlotinib

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol.
• Pathologically confirmed non-squamous NSCLC. Locally advanced or metastatic NSCLC
• EGFR sensitive mutations confirmed by accredited local laboratories， including 19del、L858R and T790M。
• Intolerant or refuses, or not suitable for systemic chemotherapy.
• Progressed after EGFR-TKI targeted therapy or are intolerant to standard treatment; if carry T790M mutation, need to be treated with osimertinib or other third-generation EGFR-TKI.
• World Health Organization performance status of 0 to 1
• Life expectancy \>12 weeks at Day 1.
• At least 1 lesion to be measured
• Females must be using highly effective contraceptive measures, and must have a negative pregnancy test prior to start of dosing if of childbearing potential, or must have evidence of non-childbearing potential by fulfilling criteria at screening.
• Male patients must be willing to use barrier contraception

You may not qualify if:

• Any known RET rearrangement, BRAF V600E mutation, NTRK fusion, MET ex14 skip mutation, MET amplification (defined as tissue detection GCN ≥ 5 by NGS)
• Any concurrent and/or other active malignancy within 2 years
• Major surgery within 4 weeks of the first dose of IP
• Any unresolved toxicities from prior therapy.
• Past medical history of ILD (interstitial lung disease)/pneumonitis, drug-induced ILD/pneumonitis, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD/pneumonitis
• Any evidence of severe or uncontrolled systemic diseases.
• Any of the following cardiac criteria:
• i) Mean resting QTc \>470 msec ii) Any clinically important abnormalities in rhythm, conduction, or morphology of resting electrocardiogram iii) Any factors that increase the risk of QTc prolongation or risk of arrhythmic events
• Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of Sunvozertinib and Anlotinib
• Severe allergies to Sunvozertinib and Anlotinib

Sponsors & Collaborators

• Shanghai Zhongshan Hospital: lead

MeSH Terms

Interventions

anlotinib

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 1, 2023
• First Posted: December 27, 2023
• Study Start: January 1, 2024
• Primary Completion: January 1, 2026
• Study Completion (Estimated): July 1, 2028
• Last Updated: December 27, 2023

Record last verified: 2023-12